Japan Women’s Health Market Size & Outlook, 2023-2030
Japan women’s health market, 2018-2030 (US$M)
Related Markets
Japan women’s health market highlights
- The Japan women’s health market generated a revenue of USD 3,080.9 million in 2023 and is expected to reach USD 5,010.1 million by 2030.
- The Japan market is expected to grow at a CAGR of 7.2% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
Women’s health market data book summary
| Market revenue in 2023 | USD 3,080.9 million |
| Market revenue in 2030 | USD 5,010.1 million |
| Growth rate | 7.2% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, Japan accounted for 6.9% of the global women’s health market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan women’s health market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 3,966.1 million by 2030.
Contraceptives was the largest segment with a revenue share of 36.17% in 2023. Horizon Databook has segmented the Japan women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, the majority of the current population is above 50 years of age. According to UN, in 2020, around 24.83 million women in Japan were in the age group of 15 to 49 years. Moreover, according to World Bank, there were 21.11 million women aged 65 and above in 2022 in the country.
Furthermore, increase in the prevalence of endometriosis and postmenopausal osteoporosis is a key factor boosting the market growth. According to the International Osteoporosis Foundation, the prevalence of osteoporosis is around 13 million, with a notable increase each year.
For instance, in 2022, Japan's fertility rate was 1.36 births per woman. In comparison, the global average fertility rate is approximately 2.42 births per woman. Such factors are anticipated to boost the women's health market in the country over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan women’s health market size, by application, 2018-2030 (US$M)
Japan Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
